Pricing adjustments for CAR-T therapies likely to take place in 2018, says analyst

4 April 2018
2019_biotech_test_vial_discovery_big

Despite the promising findings that the currently approved chimeric antigen receptor T-cell (CAR-T) immuno-oncology (I-O) therapies – Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) – are beneficial, practical challenges associated with their pricing and reimbursement remain.

New research from analytics company GlobalData points out that, currently, Novartis’ (NOVN: VX) Kymriah and Gilead/Kite Pharma/Gilead Sciences’ (Nasdaq: GILD) Yescarta are the only CAR-T cell therapies available in the US market. The labels for both drugs contain boxed warnings for severe adverse events - cytokine release syndrome as well as neurologic toxicities.

Upon launch, Kymriah (August 2017) and Yescarta (October 2017) were priced at $475,000 and $373,000 per treatment, respectively, placing these among the highest-priced drugs on the oncology market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology